Kyverna Therapeutics KYTX Cash Flow Statement (2022-2026)

NASDAQ KYTX
$5.12 +0.04 (+0.79%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Kyverna Therapeutics Quarterly Cash Flow Statement

Periods 15 quarters
Latest Jun 2026

Kyverna Therapeutics reported cash from operations of -$40.30M and free cash flow of -$40.30M for the quarter ended Jun 2026, down 26.0% year over year. This cash flow statement covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -11.14M-13.09M-15.47M-20.70M-26.69M-28.80M-34.49M-37.50M-44.64M-42.08M-36.79M-37.80M-39.73M-38.32M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort. 0.39M0.41M0.44M0.46M0.48M0.53M0.56M0.56M0.50M0.52M0.42M0.37M0.35M0.43M
Share-based CompensationStock Comp. 0.47M0.45M0.52M0.78M2.28M1.28M3.41M1.38M2.16M2.52M2.70M2.70M3.17M3.51M
Gains from Sales and DivestituresGains Divest -0.04M-0.02M
Asset Writedowns and ImpairmentWritedown 0.65M
Other non-cash itemsOther Non-Cash 0.38M0.44M0.44M0.45M0.53M0.66M0.67M0.69M0.70M0.72M0.73M0.82M0.73M0.46M
Change in Working Capital
Change in Account PayablesChange Payables 0.11M0.49M0.51M2.98M3.07M-2.10M5.07M-5.30M3.78M1.41M-6.80M2.15M6.28M-8.65M
Change in Accrued ExpensesChange Accrued Exp. -0.78M0.50M0.72M0.96M-1.45M1.36M1.72M0.44M-1.80M1.89M1.99M3.03M-6.88M2.37M
Change in Other Operating AssetsOther Assets Change 0.60M0.17M-0.52M2.80M2.87M-3.07M1.86M1.80M0.90M-2.36M2.10M-0.54M-0.06M-0.95M
Change in Other Operating LiabilitiesOther Liabilities Change -0.34M-0.43M-0.44M-0.46M-0.52M-0.61M-0.33M-0.94M-0.96M-0.76M-0.77M-3.34M-0.50M-0.73M
Other Working Capital ChangesOther WC Changes -0.94M-0.60M0.08M-3.26M-3.39M2.46M-2.19M-2.74M-1.86M1.60M-2.87M-2.80M-0.44M0.22M
Cash from OperationsCash from Ops. -11.46M-11.26M-11.13M-18.56M-25.53M-24.18M-27.49M-37.11M-44.92M-31.99M-43.29M-33.53M-41.60M-40.30M
Investing Activities
Capital ExpendituresCapex 0.03M0.00M0.26M0.33M0.54M1.03M0.10M0.53M0.00M0.00M0.00M
Change in Property, Plant and EquipmentChange in PP&E -0.03M0.00M-0.26M-0.33M-0.54M-1.03M-0.10M-0.53M0.00M0.00M0.00M
Change in IntangiblesChange Intangibless 0.39M0.54M
Sale and Maturity of InvestmentsInvestments Sold 13.68M33.00M23.00M13.00M138.30M157.00M86.70M124.10M95.70M99.20M65.70M68.60M
Other Investing Activities (as filed)Other investing (as filed) 0.56M0.00M0.00M0.00M0.57M0.00M-0.01M-0.01M0.56M-0.01M0.55M
Cash from Investing ActivitiesCash from Investing 13.66M0.00M-54.12M31.68M-122.88M-67.92M0.68M29.22M5.58M29.17M22.56M-17.29M-50.20M36.13M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment 0.17M0.19M0.21M0.22M0.23M0.25M0.24M0.25M0.34M0.26M0.12M0.09M0.09M0.10M
Net Long-Term Debt Issued (Repaid)Net LT Debt -0.17M-0.19M-0.21M-0.22M-0.23M-0.25M-0.24M-0.25M-0.34M-0.26M-0.12M-0.09M-0.09M-0.10M
Net Debt Issuances and RepaymentsNet Debt Issuance -0.17M-0.19M-0.21M-0.22M-0.23M-0.25M-0.24M-0.25M-0.34M-0.26M-0.12M-0.09M-0.09M-0.10M
Change in Capital Stock
Common Stock IssuedStock Issued 0.02M0.04M0.31M0.28M341.24M0.07M0.09M0.03M0.00M1.65M116.24M0.24M4.14M
Net Shares Issued and RepurchasedNet Shares Issued 0.02M0.04M0.31M0.28M341.24M0.07M0.09M0.03M0.00M1.65M116.24M0.24M4.14M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued 34.84M
Net Equity Issued and RepurchasedNet Equity Issued 0.02M0.04M35.15M0.28M341.24M0.07M0.09M0.03M0.00M1.65M116.24M0.24M4.14M
Other financing activities (as filed) -1.49M-2.96M-0.41M-0.08M-0.34M-0.06M-0.07M-0.07M
Cash from Financing ActivitiesCash from Financing -0.14M24.91M34.79M-1.43M338.05M-0.57M-0.15M-0.22M-0.41M-0.65M1.49M140.74M-0.10M3.79M
Additional items
Change in Cash 2.05M13.65M-30.46M11.68M189.65M-92.67M-26.97M-8.05M-39.75M-3.43M-19.28M89.93M-91.90M-0.39M
Ending Cash Balance 38.29M39.79M53.43M22.97M35.21M224.29M131.62M104.66M97.17M56.87M53.44M34.16M124.64M32.19M31.81M
Free Cash FlowFCF -11.49M-11.26M-11.39M-18.90M-26.07M-25.20M-27.59M-37.64M-44.92M-31.99M-43.29M-33.53M-41.60M-40.30M
Net Cash FlowNCF 2.05M13.65M-30.46M11.68M189.65M-92.67M-26.97M-8.10M-39.75M-3.47M-19.24M89.93M-91.90M-0.39M
Interest Paid 0.04M0.05M0.05M0.05M0.04M0.04M0.03M0.03M0.02M0.02M0.01M0.37M0.57M0.57M

Kyverna Therapeutics Cash Flow Statement API

Pull Kyverna Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=KYTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY